FDA approved Kite CAR-T therapy Yescarta for second-line lymphoma
- EPA Announces First-Ever Regulation for “Forever Chemicals” in Drinking Water
- Kochi University pioneers outpatient bladder cancer treatment using semiconductor lasers
- ASPEN 2024: Nutritional Therapy Strategies for Cancer and Critically Ill Patients
- Which lung cancer patients can benefit from neoadjuvant immunotherapy?
- Heme Iron Absorption: Why Meat Matters for Women’s Iron Needs
- “Miracle Weight-loss Drug” Semaglutide Is Not Always Effective
FDA approved Kite CAR-T therapy Yescarta for second-line lymphoma
- Red Yeast Rice Scare Grips Japan: Over 114 Hospitalized and 5 Deaths
- Long COVID Brain Fog: Blood-Brain Barrier Damage and Persistent Inflammation
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
FDA approved Kite CAR-T therapy Yescarta for second-line lymphoma.
On April 02, the U.S. Food and Drug Administration announced that it has approved the expanded scope of Yescarta (axicabtagene ciloleucel), a CD19-targeted CAR-T therapy developed by Kite Pharma, a subsidiary of Gilead Sciences, for the second-line treatment of adult patients with large B-cell lymphoma (LBCL).
They developed resistance after receiving first-line chemoimmunotherapy, or relapsed within 12 months of first-line therapy.
This therapy is not indicated for the treatment of patients with primary central nervous system lymphoma. According to a press release from Kite Pharma, this is “the first approved therapy to improve patient outcomes compared to standard therapy in nearly 30 years.”
Yescarta is the second FDA-approved CAR-T cell therapy, which guides and activates T cells to kill cancerous B cells by targeting the CD19 antigen on the surface of B cells.
This approval is based on positive results from the randomized, open-label clinical trial ZUMA-7. A total of 359 patients were randomized to receive a single dose of Yescarta or standard second-line therapy. The primary efficacy endpoint was event-free survival (EFS). Results of the trial showed that patients in the Yescarta group had significantly longer EFS (HR=0.40, 95% CI: 0.31, 0.51; p<0.0001). The estimated EFS was 8.3 months in the Yescarta group and 2.0 months in the standard-care group. The independent review committee-assessed objective response rate in the Yescarta group was 83%, which was significantly better than the 50% in the control group.
In terms of safety, 90% of treated non-Hodgkin lymphoma patients developed cytokine release syndrome (CRS), and the proportion of grade 3 or higher CRS was 9%. The incidence of neurotoxicity was 78% (grade 3 or higher, 25%).
Christi Shaw, Chief Executive Officer of Kite, said: “Kite started with a very bold goal: to create hope for survival through cell therapy. Today’s FDA approval enables the power of CAR-T cell therapy to be harnessed earlier in the therapeutic journey, providing the More patients bring hope!”
References:
[1] FDA approves axicabtagene ciloleucel for second-line treatment of large B-cell lymphoma. Retrieved April 1, 2022, from https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves- axicabtagene-ciloleucel-second-line-treatment-large-b-cell-lymphoma
[2] Yescarta® Receives US FDA Approval as First CAR T-cell Therapy for Initial Treatment of Relapsed or Refractory Large B-cell Lymphoma (LBCL).
FDA approved Kite CAR-T therapy Yescarta for second-line lymphoma
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.
